FDA Approves Accord BioPharma’s IMULDOSA for Treating Chronic Inflammatory Conditions
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., which focuses on oncology, immunology, and critical care therapies, has announced the FDA approval of IMULDOSA (uste ...
Capricor Therapeutics Begins BLA Submission for Deramiocel to Treat DMD Cardiomyopathy
Capricor Therapeutics, a biotechnology company dedicated to developing transformative cell and exosome-based therapeutics for rare diseases, has announced the initiation of its rolling submission proc ...
Dizal’s Sunvozertinib Receives Breakthrough Therapy Designation for First-Line NSCLC Treatment
Dizal, a biopharmaceutical company dedicated to the development of novel treatments for cancer and immunological diseases, has announced that the Center for Drug Evaluation (CDE) of China's National M ...
Clearmind Medicine Receives IRB Approval for Phase I/IIa Clinical Trial of CMND-100 Targeting Alcohol Use Disorder
Clearmind Medicine Inc., a clinical-stage biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics for major under-treated health issues, has received ...
FDA Grants Breakthrough Therapy Designation to Mirum’s Volixibat for Cholestatic Pruritus in PBC
Mirum Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has awarded Breakthrough therapy designation to their drug, volixibat, as a potential treatment for cholestat ...